A self-adjuvant multiantigenic nanovaccines simultaneously activate the antiviral and antitumor immunity for the treatment of cancers
Open Access
- 27 February 2025
- journal article
- research article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-13
Abstract
Tumor cell-derived extracellular vesicles (tEVs) have garnered significant attention as promising antigen delivery vehicles for the development of cancer vaccines. However, their practical applications are hindered by weak immunogenicity and inadequate lymph node targeting. In this study, we engineered tEVs into “self-adjuvant” multiantigenic nanovaccines that simultaneously accumulate in tumors and lymph nodes (LNs), effectively triggering innate and adaptive immunity capable of recognizing both tumor cells and virus antigen-modified tumor cells to inhibit tumor progression. 4T1 tumor cells were infected with vesicular stomatitis virus (VSV), leading to the expression of VSVG and calreticulin (CRT) on their surface. Using these infected cells, we prepared extracellular vesicles (vEVs) carrying both VSVG and CRT. When injected subcutaneously, vEVs targeted tumors effectively due to the homologous targeting capability of tumor cell membranes. In which, VSVG induced fusion between vEVs and tumor cells, creating viral antigen-decorated tumor cells, which enhanced the recognition and phagocytosis of tumor cells by macrophages. Additionally, the surface CRT of vEVs activated the “eat-me” signaling, thus improving their recognition and uptake by dendritic cells (DCs). This led to DC maturation and the activation of antiviral and antitumor T cells, synergistically inhibiting tumor growth. This research introduces a straightforward yet efficacious methodology for the production of cancer vaccines to fight cancer through the stimulation of both the antiviral and antitumor immune responses within the body.Keywords
Funding Information
- National Natural Science Foundation of China (22274011)
- Hebei Natural Science Foundation (B2024105013)
- Beijing Natural Science Foundation Proposed Program (L242138)
This publication has 23 references indexed in Scilit:
- Engineered extracellular vesicles: A new approach for targeted therapy of tumors and overcoming drug resistanceCancer Communications, 2023
- Challenges in developing personalized neoantigen cancer vaccinesNature Reviews Immunology, 2023
- Standardization Approaches for Extracellular Vesicle Loading with Oligonucleotides and BiologicsSmall, 2023
- Engineering Oncolytic Adenoviruses with VSVG‐Decorated Tumor Cell Membranes for Synergistically Enhanced Antitumor TherapyAdvanced Functional Materials, 2022
- Next generation of neurological therapeutics: Native and bioengineered extracellular vesicles derived from stem cellsAsian Journal of Pharmaceutical Sciences, 2022
- Enteric viruses replicate in salivary glands and infect through salivaNature, 2022
- Highly Attenuated Recombinant Vesicular Stomatitis Virus VSV-12′GFP Displays Immunogenic and Oncolytic ActivityJournal of Virology, 2013
- Autophagy Is an Essential Component of Drosophila Immunity against Vesicular Stomatitis VirusImmunity, 2009
- Dendritic Cell-Based Tumor Vaccines and Antigen Presentation AttenuatorsMolecular Therapy, 2006
- Vesicular stomatitis virus: re-inventing the bulletTrends in Molecular Medicine, 2004